Related Companies
|
[]
|
||||||||
Related Funds
|
[]
|
||||||||
|
|||||||||
English
|
|||||||||
oda_MaterialEventDisclosureGeneralAbstract|
|
|
||||||||
oda_UpdateAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
oda_CorrectionAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
oda_DateOfThePreviousNotificationAboutTheSameSubject|
|
|
-
|
|||||||
oda_DelayedAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
oda_AnnouncementContentSection|
|
|
||||||||
oda_ExplanationSection|
|
|
||||||||
oda_ExplanationTextBlock|
|
-Unofficial Translation-
The projects titled "Oral Treatment Product Containing Methoxsalen for Use in the Treatment of Psoriasis" and "A New Active Substance (SUL-238) for the Treatment of Neurodegenerative Diseases", developed by GEN İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş., have been deemed eligible for support under the "Technology-Oriented Industry Move Program – Emerging Innovative Technologies Call."
Detailed information is available on our corporate website.
|